PortfoliosLab logoPortfoliosLab logo
AMPH vs. GLEN.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AMPH vs. GLEN.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amphastar Pharmaceuticals, Inc. (AMPH) and Glencore plc (GLEN.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

AMPH is traded in USD, while GLEN.L is traded in GBp. To make them comparable, the GLEN.L values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, AMPH achieves a -24.98% return, which is significantly lower than GLEN.L's 45.81% return. Over the past 10 years, AMPH has underperformed GLEN.L with an annualized return of 2.48%, while GLEN.L has yielded a comparatively higher 20.32% annualized return.


AMPH

1D
-2.14%
1M
16.13%
YTD
-24.98%
6M
-20.50%
1Y
-22.19%
3Y*
-24.72%
5Y*
0.17%
10Y*
2.48%

GLEN.L

1D
2.39%
1M
-1.48%
YTD
45.81%
6M
58.94%
1Y
106.32%
3Y*
15.24%
5Y*
16.73%
10Y*
20.32%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AMPH vs. GLEN.L - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AMPH
Amphastar Pharmaceuticals, Inc.
-24.98%-27.88%-39.97%120.74%20.31%15.81%4.25%-3.07%3.43%4.45%
GLEN.L
Glencore plc
45.81%27.27%-24.64%-1.15%40.33%65.47%2.03%-11.04%-26.31%56.59%

Correlation

The correlation between AMPH and GLEN.L is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.06

Correlation (5Y)
Calculated over the trailing 5-year period

0.08

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Jun 25, 2014

0.11

Fundamentals

Market Cap

AMPH:

$933.34M

GLEN.L:

£71.06B

EPS

AMPH:

$1.67

GLEN.L:

-$0.10

PS Ratio

AMPH:

1.32

GLEN.L:

0.20

PB Ratio

AMPH:

1.21

GLEN.L:

2.45

Total Revenue (TTM)

AMPH:

$720.53M

GLEN.L:

$479.07B

Gross Profit (TTM)

AMPH:

$341.13M

GLEN.L:

$11.90B

EBITDA (TTM)

AMPH:

$155.96M

GLEN.L:

$19.53B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AMPH vs. GLEN.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMPH
AMPH Risk / Return Rank: 2323
Overall Rank
AMPH Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
AMPH Sortino Ratio Rank: 2525
Sortino Ratio Rank
AMPH Omega Ratio Rank: 2424
Omega Ratio Rank
AMPH Calmar Ratio Rank: 2424
Calmar Ratio Rank
AMPH Martin Ratio Rank: 2020
Martin Ratio Rank

GLEN.L
GLEN.L Risk / Return Rank: 9696
Overall Rank
GLEN.L Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
GLEN.L Sortino Ratio Rank: 9696
Sortino Ratio Rank
GLEN.L Omega Ratio Rank: 9595
Omega Ratio Rank
GLEN.L Calmar Ratio Rank: 9696
Calmar Ratio Rank
GLEN.L Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AMPH vs. GLEN.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amphastar Pharmaceuticals, Inc. (AMPH) and Glencore plc (GLEN.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AMPHGLEN.LDifference
Sharpe ratioReturn per unit of total volatility

-3.66

Sortino ratioReturn per unit of downside risk

-4.20

Omega ratioGain probability vs. loss probability

0.95

1.49

-0.54

Calmar ratioReturn relative to maximum drawdown

-0.53

7.07

-7.60

Martin ratioReturn relative to average drawdown

-1.07

21.94

-23.01

AMPH vs. GLEN.L - Sharpe Ratio Comparison

The current AMPH Sharpe Ratio is -0.45, which is lower than the GLEN.L Sharpe Ratio of 3.22. The chart below compares the historical Sharpe Ratios of AMPH and GLEN.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AMPH vs. GLEN.L - Drawdown Comparison

The maximum AMPH drawdown since its inception was -74.05%, smaller than the maximum GLEN.L drawdown of -88.55%. Use the drawdown chart below to compare losses from any high point for AMPH and GLEN.L.


Loading charts...

Drawdown Indicators


AMPHGLEN.LDifference

Max Drawdown

Largest peak-to-trough decline

-74.05%

-88.55%

+14.50%

Max Drawdown (1Y)

Largest decline over 1 year

-45.25%

-14.96%

-30.29%

Max Drawdown (3Y)

Largest decline over 3 years

-74.05%

-53.53%

-20.52%

Max Drawdown (5Y)

Largest decline over 5 years

-74.05%

-54.01%

-20.04%

Max Drawdown (10Y)

Largest decline over 10 years

-74.05%

-75.39%

+1.34%

Current Drawdown

Current decline from peak

-69.09%

-4.75%

-64.34%

Average Drawdown

Average peak-to-trough decline

-24.08%

-40.97%

+16.89%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.54%

4.83%

+17.71%

Volatility

AMPH vs. GLEN.L - Volatility Comparison

Amphastar Pharmaceuticals, Inc. (AMPH) has a higher volatility of 12.20% compared to Glencore plc (GLEN.L) at 11.37%. This indicates that AMPH's price experiences larger fluctuations and is considered to be riskier than GLEN.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AMPHGLEN.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.20%

11.37%

+0.83%

Volatility (6M)

Calculated over the trailing 6-month period

46.17%

24.07%

+22.10%

Volatility (1Y)

Calculated over the trailing 1-year period

53.78%

32.88%

+20.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

45.07%

35.19%

+9.88%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

42.71%

38.23%

+4.48%

Dividends

AMPH vs. GLEN.L - Dividend Comparison

AMPH has not paid dividends to shareholders, while GLEN.L's dividend yield for the trailing twelve months is around 1.70%.


PositionTTM202520242023202220212020201920182017
AMPH
Amphastar Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GLEN.L
Glencore plc
1.70%1.84%2.87%8.72%5.58%3.08%0.00%6.70%5.16%1.37%

Financials

AMPH vs. GLEN.L - Financials Comparison

This section allows you to compare key financial metrics between Amphastar Pharmaceuticals, Inc. and Glencore plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B120.00B140.00B20222023202420252026
171.17M
130.73B
(AMPH) Total Revenue
(GLEN.L) Total Revenue
Values in USD except per share items

AMPH vs. GLEN.L - Profitability Comparison

The chart below illustrates the profitability comparison between Amphastar Pharmaceuticals, Inc. and Glencore plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%10.0%20.0%30.0%40.0%50.0%60.0%20222023202420252026
41.1%
2.6%
Portfolio components
AMPH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Amphastar Pharmaceuticals, Inc. reported a gross profit of 70.32M and revenue of 171.17M. Therefore, the gross margin over that period was 41.1%.

GLEN.L - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Glencore plc reported a gross profit of 3.44B and revenue of 130.73B. Therefore, the gross margin over that period was 2.6%.

AMPH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Amphastar Pharmaceuticals, Inc. reported an operating income of 13.63M and revenue of 171.17M, resulting in an operating margin of 8.0%.

GLEN.L - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Glencore plc reported an operating income of 2.18B and revenue of 130.73B, resulting in an operating margin of 1.7%.

AMPH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Amphastar Pharmaceuticals, Inc. reported a net income of 6.42M and revenue of 171.17M, resulting in a net margin of 3.8%.

GLEN.L - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Glencore plc reported a net income of 1.02B and revenue of 130.73B, resulting in a net margin of 0.8%.


Frequently Asked Questions


AMPH and GLEN.L have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for AMPH and GLEN.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer